Related Experiment Video

Updated: May 8, 2026

Assessment of Human Adipose Tissue Microvascular Function Using Videomicroscopy
07:24

Assessment of Human Adipose Tissue Microvascular Function Using Videomicroscopy

Published on: September 29, 2017

The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function

Belqes Abdullah Mohammad Al-Tahami1, Ab Aziz Al-Safi Ismail2, Yvonne Tee Get Bee3

  • 1Pharmacology Vascular Laboratory, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.

Clinical Hemorheology and Microcirculation
|September 5, 2013
PubMed

Insights

Orlistat treatment significantly improved microvascular endothelial function in obese patients, associated with weight loss and improved cardiovascular markers. Sibutramine showed no effect on endothelial function.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Pharmacology

Background:

  • Obesity is linked to impaired microvascular endothelial function.
  • Understanding the impact of anti-obesity medications on vascular health is crucial.

Purpose of the Study:

  • To evaluate the effects of orlistat and sibutramine on microvascular endothelial function.
  • To assess changes in anthropometric measures, lipid profiles, blood pressure (BP), and heart rate (HR).

Main Methods:

  • A 9-month randomized trial involving 76 obese subjects.
  • Treatment groups received either orlistat or sibutramine.
  • Microvascular endothelial function assessed via laser Doppler fluximetry and iontophoresis (acetylcholine and sodium nitroprusside).

Main Results:

  • Orlistat treatment led to significant improvements in endothelium-dependent vasodilation (AChmax, ACh % change, ACh peak).
  • Orlistat also reduced weight, BMI, BP, HR, total cholesterol, and LDL cholesterol.
  • Sibutramine treatment did not improve microvascular endothelial function and increased HR.

Conclusions:

  • Orlistat effectively improves microvascular endothelial function in obese individuals.
  • The benefits of orlistat are linked to weight reduction and improvements in cardiovascular risk factors.
  • Sibutramine lacks beneficial effects on microvascular endothelial function.
Abstract

Keywords:
Microvascular endothelial functionobesityorlistatsibutramine

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...